Do Not Initiate Ivermectin for Invasive Ductal Carcinoma
Ivermectin should absolutely not be initiated for the treatment of invasive ductal carcinoma while awaiting ultrasound evaluation or at any point in breast cancer management. There is no established role for ivermectin in breast cancer treatment, and doing so would delay or interfere with evidence-based, guideline-concordant cancer care that directly impacts survival.
Why Ivermectin Has No Role Here
FDA-Approved Indications Only
Ivermectin is FDA-approved exclusively for parasitic infections—specifically intestinal strongyloidiasis and onchocerciasis 1. The drug label contains no oncologic indications whatsoever 1. Using it for cancer treatment represents off-label use without supporting clinical trial data in humans.
No Clinical Evidence in Breast Cancer Patients
While preclinical laboratory studies show ivermectin can inhibit cancer cell growth in petri dishes and animal models 2, 3, 4, these findings have never been validated in human clinical trials for breast cancer 5. The concentrations used in laboratory experiments may not be safely achievable in patients, and cell culture results notoriously fail to translate to clinical benefit.
A recent 2025 review specifically addressing gynecologic cancers (which share similar treatment paradigms with breast cancer) explicitly states: "We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers" due to lack of safety and efficacy data 5.
What Should Actually Happen Now
Immediate Standard Workup Required
According to ESMO guidelines, before any treatment is initiated for invasive ductal carcinoma, the following must be completed 6:
- Core needle biopsy confirmation (already done in this case)
- Complete imaging evaluation including the pending ultrasound to assess:
- Tumor extent and multifocality
- Axillary lymph node involvement
- Biomarker assessment on the biopsy specimen:
- Estrogen receptor (ER) status
- Progesterone receptor (PR) status
- HER2 status
- Ki67 proliferation index
- Tumor grade
Treatment Cannot Begin Until Staging Complete
The 2025 NCCN guidelines emphasize that treatment decisions for invasive breast cancer depend entirely on complete staging and biomarker profiling 7. Starting any treatment—whether evidence-based or experimental—before completing this evaluation is inappropriate because:
- Treatment selection differs dramatically based on hormone receptor status, HER2 status, and stage
- Neoadjuvant chemotherapy decisions require knowing the full extent of disease
- Surgical planning depends on imaging findings
The Actual Harm of Using Ivermectin
Delays Effective Treatment
Every day spent on unproven therapy is a day without evidence-based treatment. For invasive ductal carcinoma, established treatments include:
- Surgery (lumpectomy or mastectomy)
- Radiation therapy
- Systemic therapy (chemotherapy, endocrine therapy, HER2-targeted therapy, or CDK4/6 inhibitors depending on biomarkers)
These treatments have decades of clinical trial data demonstrating improved survival 6, 7, 8.
False Sense of Security
Patients may believe they are "treating" their cancer with ivermectin, leading to dangerous delays in pursuing curative-intent therapy. Invasive ductal carcinoma carries metastatic potential—unlike DCIS—and delays directly impact mortality risk 9.
Potential Drug Interactions
Ivermectin can interact with warfarin (increasing INR) and potentially other medications 1. In a patient about to undergo surgery and systemic therapy, introducing unnecessary medications creates avoidable complications.
The Bottom Line
Complete the staging ultrasound immediately, obtain full biomarker results, and proceed with multidisciplinary tumor board-recommended, guideline-concordant treatment. The standard approach for invasive ductal carcinoma—surgery, radiation, and systemic therapy tailored to biomarkers—has proven survival benefits in hundreds of thousands of patients 6, 7, 8.
Ivermectin remains an antiparasitic drug. Its theoretical anticancer properties exist only in laboratory settings and have never been tested in breast cancer patients. Using it now would constitute medical experimentation outside of a clinical trial, without informed consent, and without institutional review board oversight—all while delaying treatments that actually save lives.